IBSA
12.9.2022 12:01:42 CEST | Business Wire | Press release
A real celebration was held on September 9 in the port of La Trinité-Sur-Mer, in Brittany, for the launch of the Class40 IBSA, the brand new boat with which Alberto Bona will participate in the Route du Rhum. The transatlantic regatta is indeed the first project of the three-year program Sailing into the Future. Together that the ocean sailor started with IBSA at the beginning of 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220908006032/en/
Class40 IBSA: official launch. From left to right: Sidney Gavignet, Alberto Bona, Arturo Licenziati, Giorgio Pisani, Fabrice Jover (Photo: © IBSA | Beppe Raso)
Great enthusiasm and emotion characterised the event, that took place in the small but famous Breton port, along whose mooring quays are berthed some of the most prestigious trimarans that have gone around the world and have made the history of ocean sailing. And right here, Arturo Licenziati – President and CEO of the IBSA Group – Alberto Bona and his entire team celebrated the launch of an innovative and revolutionary hull, as well as the visionary project that supports it.
“Sailing into the Future. Together is the three-year international project that we strongly pursued, because it combines several elements that for us are extremely important and distinctive: innovation, technology, commitment to sport and to the community, environmental and social responsibility”, commented Arturo Licenziati. “The whole project and this first great sporting challenge that we are preparing to face give us the opportunity to introduce to the world our vision, values and Pillars (Person, Innovation, Quality and Responsibility), the same ones that we share with sport, and with sailing in particular.”
To break the bottle on the hull – in one of the most traditional rites of the nautical world, which officially baptises the boat – will be the godmother Francesca Licenziati, niece of IBSA’s President. The launch celebration is a moment of great pride and joy, shared by the whole team, who for months worked hard on the new boat and collaborated on several fronts, concretely showing how Sailing into the Future. Together is an international project, which involves Switzerland, France and Italy in particular, and is based on strong values of inclusiveness, sustainability and teamwork.
After the technical launch on August 3, the hull designed by Sam Manuard – built by the shipyard JPS Production and hoisting the burgee of the Bellano Yacht Club – has been subject to a series of tests at sea, which allowed Alberto Bona to qualify for the Route du Rhum by sailing, between August 30 and September 5, the first 1,200 miles alone. The navigation took place in the Bay of Biscay, between Brittany and Spain, and highlighted the qualities of the hull and an excellent state of preparation in even complex weather conditions, with the winds and waves typical of the Atlantic Ocean.
“After the technical launch”, said Alberto Bona, “we had very good feedback from every perspective, from the construction of the hull to the sails, from the design to the preparation of the team. We worked to prepare the Class40 IBSA as best, and by the end of August we were ready for the qualification: on this front, we accelerated as much as possible, because after a very hot and dry summer, we had signs that the weather conditions in the Northeast Atlantic were rapidly changing.”
The Class40 IBSA thus already arrived at its launch with over 1,200 miles at sea and the first, exciting occasion of solitary navigation by Alberto Bona.
“These have been even more beautiful days than I could have imagined: on the one hand the satisfaction of now being in perfect timing for the Route du Rhum, considering that we only started the project last February; on the other the certainty of having a reliable and fast boat, the two characteristics that navigators always look for when they have to leave for a challenge like the one that awaits us from November 6, as well as all those to follow.”
“We are very satisfied with the results we have achieved so far. After many months of commitment and hard work, we have finally put into the water a boat that has all the credentials to ensure a very high performance and to be highly competitive”, commented Giorgio Pisani, Vice President Southern Europe IBSA and Project Leader. “The Class40 IBSA is the result of an approach that represents our way of being: it brings together innovation, attention to detail, continuous improvement and determination, with a vision that for IBSA always goes beyond the pharmaceutical field and beyond care.”
With this launch, the countdown to the start of the Route du Rhum has officially begun: in the coming days Alberto Bona and the team will continue working on the boat and will begin a series of targeted training sessions, in some cases working together with other teams registered in the regatta, in a series of joint tests. In mid-September, Bona will participate in the Malouine Lamotte regatta and then, on September 22, he will attend the opening day of the Genoa Boat Show, with the aim of promoting the project Sailing into the Future. Together in all its aspects, in particular that related to social inclusion.
Indeed, in its sailing programme IBSA is also committed in the field of inclusive sailing, with the involvement of prestigious yacht clubs: the Associazione Velabili, based at the Circolo Velico Lago di Lugano (Switzerland); the Société des Régates d’Antibes (France); and the Yacht Club Punta Ala (Italy). The project – which aims to support inclusive sailing, by promoting initiatives that engage people with disabilities in experiences in contact with the sea and the world of sailing – consists in supporting a team of disabled sailors in participating in the Special Olympics World Games of 2023 and in the purchase of Hansa 303 boats for the Clubs of Punta Ala and Antibes.
IBSA
IBSA (Institut Biochimique SA) is a Swiss multinational pharmaceutical Company, founded in 1945 in Lugano. Today, its products are present in over 90 Countries on 5 continents, through the Company’s 17 subsidiaries located in Europe, China, and the United States. The company has a consolidated turnover of 800 million CHF, and employs over 2,000 people between headquarters, subsidiaries and production sites. IBSA holds 90 families of approved patents, plus others under development, as well as a vast portfolio of products, covering 10 therapeutic areas: reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynaecology, cardiometabolic, respiratory, consumer health. It is also one of the largest operators worldwide in the area of reproductive medicine, and one of the world’s leaders in hyaluronic acid-based products. IBSA has based its philosophy on four pillars: Person, Innovation, Quality and Responsibility.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220908006032/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
